India Immune-Oncology Drugs Market Revenue Growth Predicted by 2026

14

Immuno-Oncology refers to the use of body’s natural defenses to fight disease. It works by stimulating the immune system instead of fighting the tumors, avoiding disturbance in functionality of healthy cells. Immuno-oncology drugs facilitates long-term response against cancer by providing long-lasting memory to the immune system. Immuno-Oncology drugs works against a wide variety of cancers, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others. Immuno-oncology uses different types of cell-based immune therapies such as monoclonal antibodies, immune checkpoint inhibitors, cytokine-based immunotherapy, cancer vaccines, and other therapies. Commercially available immune-oncology therapies include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah. India Immune-Oncology Drugs Market size was valued at US$ 172.8 million in 2018 and is expected to witness a CAGR of 13.1% over the forecast period (2018 – 2026).

Market Dynamics

Increasing prevalence of cancer in India is expected to drive India Immuno-Oncology Drugs market growth. For instance, according to National Cancer Registry Programme (NCRP), India, one woman dies of cervical cancer every 8 minutes in India. For every 2 women newly diagnosed with breast cancer, one woman dies of it in India. Furthermore, as many as 2,500 persons die every day due to tobacco-related diseases in India. Tobacco (smoked and smokeless) use accounted for around 317,928 deaths in men and women in 2018.

Increasing Incidences of Cancer Cases and Introduction of Novel Immuno-Oncology Therapies is expected to Drive Growth of the India Immune-Oncology Drugs Market

Rising incidences of cancer in India is expected to boost the immuno-oncology drugs market during the forecast period. For instance, according to Indian Council of Medical Research (ICMR) – National Institute of Cancer Prevention and Research (NICPR), incidence of breast cancer is 25.8 per 100,000 women in 2018 and is expected to reach 35 per 100,000 women in 2026.

The immune-oncology drugs market is expected to generate a high revenue, owing to increasing introduction of new novel therapies for treatment of cancer with improved therapeutic outcomes that have led to increasing success rates against cancer. Novel immune therapies can restore the ability of immune system to identify and eliminate cancer cells, which is generally suppressed during course of cancer progression. Such immuno-oncology based therapies can be tailored to attack or block particular targets. For instance, Iplimumab, a human monoclonal antibody, which blocks cytotoxic T-lymphocyte-associated antigen-4 is available.

India Immune-Oncology Drugs Market – Competitive Landscape

Key players operating in the India Immune-Oncology Drugs market include Amgen, Inc., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy’s Laboratories Ltd., Bristol – Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology Company, Reliance Life Sciences, Biocon Limited, and Hetero Drugs Limited.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2631

Detailed Segmentation:

  • India Immuno-Oncology Drugs Market, By Drug Type:

    • Immune Checkpoint Inhibitors

      • Nivolumab (Opdivo)

      • Atezolimumab (Tecentriq)

      • Pembrolizumab (Keytruda)

      • Durvalumab (Imfinzi)

    • Monoclonal Antibodies

      • Rituximab (Rituxan)

      • Trastazumab (Herceptin)

      • Bevacizumab (Avastin)

      • Nimotuzumab (Biomab EGFR)

      • Pertuzumab (Perjeta)

      • Ado-Trastuzumab Emtansine (Kadcyla)

    • Cancer Vaccines

      • Gardasil

      • Cervarix

India Immune-Oncology Drugs Market – Restraints

Major restraining factors for India immune-oncology drugs market include inadequate delivery of affordable and equitable cancer care drugs in India, which hampers the India immune-oncology drugs market. For instance, according to the data published in Lancet Journal in 2014, public expenditure on cancer in India remains below US$ 10 per person (compared to over US$ 100 per person in high-income or developed countries) and overall public expenditure on healthcare is still only slightly above 1% of the gross domestic product.

According to the same source, out-of-pocket payments, which account for over three-quarter of cancer expenditures in India are one of the greatest threats to patients and families. Moreover, higher effectiveness of cancer drugs and comparatively less availability of better alternative results restricts key players to drive down cost of cancer drugs.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com